相似文献
1
Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma.
Int J Mol Sci. 2024 Sep 30;25(19):10570. doi: 10.3390/ijms251910570.
2
Novel Clinical Trials and Approaches in the Management of Glioblastoma.
Curr Oncol Rep. 2024 May;26(5):439-465. doi: 10.1007/s11912-024-01519-4. Epub 2024 Mar 28.
3
A review of glioblastoma immunotherapy.
J Neurooncol. 2021 Jan;151(1):41-53. doi: 10.1007/s11060-020-03448-1. Epub 2020 Apr 6.
4
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Anticancer Res. 2017 Jan;37(1):21-33. doi: 10.21873/anticanres.11285.
5
Management of glioblastoma in elderly patients.
J Neurol Sci. 2017 Sep 15;380:250-255. doi: 10.1016/j.jns.2017.07.048. Epub 2017 Aug 1.
6
Combination immunotherapy strategies for glioblastoma.
J Neurooncol. 2021 Feb;151(3):375-391. doi: 10.1007/s11060-020-03481-0. Epub 2021 Feb 21.
7
RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
Life Sci. 2017 Nov 1;188:26-36. doi: 10.1016/j.lfs.2017.08.027. Epub 2017 Aug 31.
8
Recent advances in therapy for glioblastoma.
Arch Neurol. 2010 Mar;67(3):279-83. doi: 10.1001/archneurol.2010.5.
9
Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials.
Curr Opin Neurol. 2024 Dec 1;37(6):666-671. doi: 10.1097/WCO.0000000000001320. Epub 2024 Sep 11.
10
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Chin Clin Oncol. 2017 Aug;6(4):41. doi: 10.21037/cco.2017.06.29.
引用本文的文献
1
Progenitor cells, microglia, and non-coding RNAs: Orchestrators of glioblastoma pathogenesis and therapeutic resistance.
Noncoding RNA Res. 2025 Aug 5;15:85-99. doi: 10.1016/j.ncrna.2025.07.007. eCollection 2025 Dec.
2
Tumor-specific PET tracer imaging and contrast-enhanced Mri based tumor volume differences inspection of glioblastoma patients.
Sci Rep. 2025 Aug 16;15(1):30011. doi: 10.1038/s41598-025-15185-4.
3
CRISPR-Cas9 screening identifies a gene signature predictive of prognosis in glioblastoma.
Sci Rep. 2025 Jul 1;15(1):21077. doi: 10.1038/s41598-025-07815-8.
4
Functional Biomaterials: Scaffolds for Innovative Treatments.
J Funct Biomater. 2025 Apr 27;16(5):154. doi: 10.3390/jfb16050154.
5
Coordinated regulation of IGF1R by HIF1α and HIF2α enhances chemoresistance in glioblastoma.
Front Pharmacol. 2025 Apr 11;16:1575332. doi: 10.3389/fphar.2025.1575332. eCollection 2025.
6
Potential of Curcumin and Its Analogs in Glioblastoma Therapy.
Antioxidants (Basel). 2025 Mar 18;14(3):351. doi: 10.3390/antiox14030351.
7
Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches.
Med Oncol. 2025 Mar 10;42(4):97. doi: 10.1007/s12032-025-02652-1.
8
Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?
Diagnostics (Basel). 2025 Feb 11;15(4):438. doi: 10.3390/diagnostics15040438.
9
Glioblastoma Cell Migration, Invasion and Vasculogenic Mimicry Downmodulated by Novel uPAcyclin Derivatives.
Cells. 2025 Feb 12;14(4):259. doi: 10.3390/cells14040259.
本文引用的文献
1
Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice.
Nat Microbiol. 2024 Jun;9(6):1467-1482. doi: 10.1038/s41564-024-01695-w. Epub 2024 May 15.
2
CAR T-Cell Therapy for Glioblastoma.
N Engl J Med. 2024 Apr 11;390(14):1329-1332. doi: 10.1056/NEJMe2401307.
3
Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.
Neurooncol Adv. 2024 Mar 15;6(1):vdae039. doi: 10.1093/noajnl/vdae039. eCollection 2024 Jan-Dec.
4
Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas.
Curr Oncol Rep. 2024 Apr;26(4):377-390. doi: 10.1007/s11912-024-01517-6. Epub 2024 Mar 15.
5
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
Nat Med. 2024 May;30(5):1320-1329. doi: 10.1038/s41591-024-02893-z. Epub 2024 Mar 13.
6
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
N Engl J Med. 2024 Apr 11;390(14):1290-1298. doi: 10.1056/NEJMoa2314390. Epub 2024 Mar 13.
7
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
BMC Cancer. 2024 Jan 15;24(1):82. doi: 10.1186/s12885-023-11797-z.
8
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
Nat Commun. 2024 Jan 12;15(1):493. doi: 10.1038/s41467-023-43076-7.
9
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
J Clin Oncol. 2023 Nov 20;41(33):5187-5199. doi: 10.1200/JCO.23.01059. Epub 2023 Sep 29.
10
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
J Clin Oncol. 2023 Dec 20;41(36):5524-5535. doi: 10.1200/JCO.23.00493. Epub 2023 Sep 18.
Zotero 插件